| scholarly article | Q13442814 |
| P50 | author | Mark Schiffman | Q69142146 |
| Philip E. Castle | Q90438073 | ||
| Diane Solomon | Q112479624 | ||
| P2093 | author name string | Debbie Saslow | |
| P2860 | cites work | Biomarkers in cervical cancer screening | Q22306444 |
| Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study | Q24679261 | ||
| Against which human papillomavirus types shall we vaccinate and screen? The international perspective | Q28267023 | ||
| Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions | Q28301685 | ||
| The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays | Q30442823 | ||
| Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis | Q33233738 | ||
| Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial | Q34580726 | ||
| Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases | Q34627305 | ||
| Human papillomavirus and Papanicolaou tests to screen for cervical cancer | Q34702284 | ||
| Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination | Q34997604 | ||
| American Cancer Society guideline for the early detection of cervical neoplasia and cancer | Q35018624 | ||
| American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors | Q36712680 | ||
| The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report | Q36794086 | ||
| Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing | Q36815006 | ||
| 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests | Q36955449 | ||
| Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections | Q36994715 | ||
| Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role | Q37312127 | ||
| A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. | Q37315930 | ||
| Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial | Q37859219 | ||
| Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. | Q40227526 | ||
| Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types | Q44918470 | ||
| Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type | Q48571834 | ||
| The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. | Q51968734 | ||
| Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. | Q53028990 | ||
| Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. | Q53340958 | ||
| A 2‐Year Prospective Study of Human Papillomavirus Persistence among Women with a Cytological Diagnosis of Atypical Squamous Cells of Undetermined Significance or Low‐Grade Squamous Intraepithelial Lesion | Q58475803 | ||
| Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial | Q79824170 | ||
| Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial | Q81404025 | ||
| Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial | Q83938901 | ||
| P433 | issue | 10 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cervix uterine cancer | Q160105 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 3031-3035 | |
| P577 | publication date | 2008-11-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States | |
| P478 | volume | 113 |
| Q37312746 | Age-appropriate use of human papillomavirus vaccines in the U.S. |
| Q37802640 | Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. |
| Q37312127 | Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role |
| Q40155311 | Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study. |
| Q35889801 | Evolution of cervical cancer screening and prevention in United States and Canada: implications for public health practitioners and clinicians |
| Q56781013 | Gardasil needs a new consent form |
| Q57476752 | Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results |
| Q33883581 | Impact of improved classification on the association of human papillomavirus with cervical precancer |
| Q36409759 | Physicians' intentions to change pap smear frequency following human papillomavirus vaccination |
| Q37315949 | Preventing cervical cancer : overviews of the National Breast and Cervical Cancer Early Detection Program and 2 US immunization programs |
| Q90700370 | Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results |
| Q43644945 | Toward using National Cancer Surveillance data for preventing and controlling cervical and other human papillomavirus-associated cancers in the US. |
| Q37539295 | Uptake in cancer screening programmes |
Search more.